Compounds > dopexamine
Page last updated: 2024-09-23

dopexamine

Description

dopexamine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55483
CHEMBL ID77622
CHEBI ID135507
SCHEMBL ID122233
MeSH IDM0134272

Synonyms (44)

Synonym
CHEMBL77622
fpl-60278
dopexamine (usan/inn)
D03891
86197-47-9
dopexamine
4-(2-((6-(phenethylamino)hexyl)amino)ethyl)pyrocatechol
1,2-benzenediol, 4-(2-((6-((2-phenylethyl)amino)hexyl)amino)ethyl)-
c22h32n2o2
dopexaminum [latin]
fpl 60278
dopexamina [spanish]
CHEBI:135507
L003335
NCGC00184998-01
unii-398e7z7jb5
398e7z7jb5 ,
dopexamine [usan:inn:ban]
dopexaminum
dopexamina
dtxcid9028592
tox21_113031
cas-86197-47-9
dtxsid2048666 ,
AKOS016014049
FT-0630938
SCHEMBL122233
NCGC00184998-02
tox21_113031_1
4-[2-[[6-(phenethylamino)hexyl]amino]ethyl]pyrocatechol
dopexamine [who-dd]
dopexamine [mi]
dopexamine [inn]
dopexamine [usan]
4-(2-((6-(phenethylamino)hexyl)amino)ethyl)benzene-1,2-diol
4-[2-({6-[(2-phenylethyl)amino]hexyl}amino)ethyl]benzene-1,2-diol
DB12313
4-(2-(6-(phenethylamino)hexylamino)ethyl)benzene-1,2-diol
Q5297311
4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol
A917656
4-[2-[[6-(phenethylamino)hexyl]amino]ethyl]-1,2-benzenediol
EN300-19767543
dopexamine-d3hydrochloride

Research Excerpts

Overview

ExcerptReference
"Dopexamine is a dopamine analog that has been used for hemodynamic optimization in a number of clinical settings. "( Hollenberg, SM, 2013)
"Dopexamine is a synthetic catecholamine, which has positive inotropic and vasodilating properties."( Akintürk, H; Koch, T; Kwapisz, MM; Löhr, T; Müller, M; Neuhäuser, C; Scholz, S; Thul, J; Valeske, K; Welters, ID, 2009)
"Dopexamine is a substance with strong beta2-adrenergic effects and is used in the treatment of critically ill patients."( Exton, M; Oberbeck, R; Schedlowski, M; Schmitz, D; Schüler, M; Wilsenack, K, 2004)
"Dopexamine hydrochloride is a new synthetic catecholamine for intravenous use in low cardiac output states with co-existing raised systemic or pulmonary vascular resistance. "( Martin, C; Papazian, L; Perrin, G, 1993)
"Dopexamine hydrochloride is a synthetic dopamine analogue recently developed to improve myocardial and renal performance in patients suffering from low cardiac output states. "( Amenta, F; Cavallotti, C; Napoleone, P; Ricci, A, 1993)
"Dopexamine hydrochloride is a novel synthetic adrenergic agonist that combines the renal effects of dopamine with the hemodynamic effects of dobutatmine. "( Butterworth, JF; James, R; MacGregor, DA; Prielipp, RC; Royster, RL; Zaloga, CP, 1994)
"Dopexamine hydrochloride is a new dopamine analogue with action at beta 2-adrenoceptors and DA1 receptors, but it possesses no direct alpha-adrenoceptor activity."( Bennett, ED; Boyd, O; Grounds, RM, 1993)
"Dopexamine is a synthetic catecholamine with predominantly beta 2 and dopaminergic adrenergic receptor activities. "( Rogers, BW; Sziszak, TJ; Sziszak, TL; Taylor, BJ, 1993)
"Dopexamine is a specific dopaminergic and beta2-adrenergic agonist. "( Choe, EU; Ferrara, JJ; Flint, LM; Mero, KA, 1998)
"Dopexamine is a synthetic vasoactive catecholamine with beneficial microcirculatory properties."( Boldt, J; Hempelmann, G; Padberg, W; Papsdorf, M; Piper, S, 1998)
"Dopexamine is a synthetic catecholamine used for the management of low-cardiac-output states. "( Calixto, JB; Dias, MA; Mazzuco, TL, 1999)
"Dopexamine (DPX) is a novel synthetic agent that has potent B2-adrenoceptor and dopaminergic activity, the clinical effects of which include an increase in cardiac output and in mesenteric blood flow."( Aliabadi-Wahle, S; Choe, EU; Ferrara, JJ; Flint, LM, 1999)
"Dopexamine (DX) is a commonly used catecholamine which probably exerts a selective effect at the splanchnic bed."( Dehne, MG; Hempelmann, G; Klein, TF; Mühling, J; Osmer, C; Sablotzki, A, 2001)
"Dopexamine hydrochloride is a new combined beta 2-adrenergic and DA1-dopaminergic receptor agonist and an inhibitor of the uptake-1 mechanism of endogenous catecholamines."( Santman, FW, 1992)
"Dopexamine hydrochloride is a synthetic catecholamine proposed for the short-term treatment of heart failure and postoperative low cardiac output. "( Amenta, F; Ferrante, F; Napoleone, P; Ricci, A, 1992)
"Dopexamine hydrochloride is a new synthetic catechol that offers a unique profile of adrenergic and dopaminergic activity. "( Elkayam, U; Gollub, SB; Haffey, KA; Miller, LW; Young, JB, 1991)
"Dopexamine hydrochloride is a novel synthetic catecholamine, structurally related to dopamine, with marked intrinsic agonist activity at beta 2-adrenoceptors, lesser agonist activity at dopamine DA1- and DA2-receptors and beta 1-adrenoceptors, and an inhibitory action on the neuronal catecholamine uptake mechanism. "( Benfield, P; Fitton, A, 1990)
"Dopexamine hydrochloride is a novel compound with properties of DA1-dopaminergic and beta 2-adrenergic receptor agonism and neuronal noradrenaline uptake inhibition. "( Littler, WA; Murray, RG; Tan, LB, 1991)
"2. Dopexamine hydrochloride is a new synthetic catecholamine."( Bodenham, AR; Burns, A; Gray, PA; Park, GR, 1990)
"Dopexamine hydrochloride is a new analog of dopamine that lowers systemic vascular resistance and has positive inotropic and chronotropic properties, but lacks the alpha-adrenoceptor agonist activity of dopamine. "( Barnes, PJ; Evans, TW; McCormack, DG, 1990)
"1. Dopexamine is a novel analogue of dopamine which is free of alpha-adrenoceptor activity and is of therapeutic value in chronic heart failure. "( Hendra, TJ; Smith, CC; Wagaine-Twabwe, D; Yudkin, JS, 1990)
"Dopexamine (FPL 60278) is a new vasodilator possessing both postjunctional dopaminergic and beta 2-adrenoceptor agonist actions. "( Bayliss, J; Poole-Wilson, P; Thomas, L, 1987)
"Dopexamine is a novel compound that has DA1-dopaminergic and beta 2-adrenergic agonist properties capable of producing beneficial systemic and renal vasodilation. "( Littler, WA; Murray, RG; Tan, LB, 1987)
"Dopexamine is a new dopamine receptor agonist which also inhibits the uptake of norepinephrine (NE) into sympathetic nerves. "( Bass, AS; Goldberg, LI; Kohli, JD; Murphy, MB, 1989)
"Dopexamine is a newly developed sympathetic catecholamine which combines dopaminergic (DA-1) and beta 2-adrenergic agonist activity with only minor beta 1-adrenergic action. "( Drexler, H; Just, H; Meinertz, T, 1989)
"Dopexamine is a new dopamine analogue, with combined agonist properties on dopamine receptors and the beta 2-adrenoceptor. "( Koolen, JJ; Mungroop, HE; Poelaert, JI; Van den Berg, PC, 1989)
"Dopexamine is an agonist at peripheral dopamine receptors and at beta 2-adrenoceptors. "( Brown, RA; Dixon, J; Farmer, JB; Hall, JC; Humphries, RG; Ince, F; O'Connor, SE; Simpson, WT; Smith, GW, 1985)
"Dopexamine (FPL 60278) is a new dopamine analogue which possesses a combination of dopamine receptor and beta-2-adrenoreceptor agonist properties. "( Erhardt, L; Sjögren, A; Svensson, G, 1986)
"Dopexamine is a new vasodilator with a combination of dopamine receptor and beta 2 adrenoreceptor agonist properties. "( Erhardt, L; Lindvall, B; Strandberg, LE; Svenson, G, 1988)
"Dopexamine hydrochloride is a new intravenous, short-acting agent with agonist activity at beta 2-adrenergic and DA1-dopaminergic receptors. "( Chatterjee, K; De Marco, T; Kwasman, M; Lau, D, 1988)
"Dopexamine hydrochloride is a novel beta 2- and dopaminergic-receptor agonist proposed for intravenous therapy in patients with congestive heart failure. "( Jaski, BE; Peters, C, 1988)
"Dopexamine hydrochloride is an effective and well-tolerated sympathomimetic agent that increases cardiac index while promoting vasodilatation."( Emmot, WW; Gollub, SB; Hassanein, K; Johnson, DE; Sights, KA; Vacek, JL; Wilson, DB, 1988)

Effects

ExcerptReference
"Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."( Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1997)
"Dopexamine has a chronotropic effect and results in a decrease in systemic vascular resistance."( Foulds, R; Jaski, BE; Serruys, PW; Wijns, W, 1986)
"Dopexamine has been shown to reduce both mortality and morbidity in major surgery when it is used as part of a protocol to increase oxygen delivery in the perioperative period. "( Davies, SJ; Wilson, RJ; Yates, D, 2011)
"Dopexamine has assumed effects on carbohydrate, fat and protein metabolism."( Ensinger, H; Geisser, W; Georgieff, M; Hofbauer, H; Vogt, J; Wachter, U, 2004)
"Dopexamine has no or only weak effects on carbohydrate metabolism, its effects on fat and protein metabolism are comparable to those of fenoterol. "( Ensinger, H; Geisser, W; Georgieff, M; Hofbauer, H; Vogt, J; Wachter, U, 2004)
"Dopexamine hydrochloride has interesting vasodilator properties, with marked intrinsic agonist activity at beta-2 adrenoreceptors and a lesser agonist activity at dopaminergic receptors (DA1 and DA2)."( Martin, C; Papazian, L; Perrin, G, 1993)
"Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."( Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1997)
"Dopexamine has been suggested to improve splanchnic perfusion but because these effects remain somewhat controversial, there is as yet no reason for a general recommendation for dopexamine in septic patients."( Meier-Hellmann, A; Reinhart, K; Sakka, SG, 2000)
"Dopexamine has been suggested for improvement of splanchnic perfusion, but since these effects remain somewhat controversial there are no current grounds for a general recommendation in favour of dopexamine in septic patients."( Meier-Hellmann, A; Reinhart, K; Sakka, SG, 2000)
"Dopexamine hydrochloride has no affinity for the uptake-2 mechanism in this tissue."( Nedergaard, OA, 1989)
"Dopexamine has approximately one-third the potency of dopamine in stimulating the vascular DA1-receptor in the dog, resulting in a fall in renal vascular resistance of 20% at 2.3 X 10(-8) mol kg-1 (i.a.)."( Brown, RA; Dixon, J; Farmer, JB; Hall, JC; Humphries, RG; Ince, F; O'Connor, SE; Simpson, WT; Smith, GW, 1985)
"Dopexamine has a chronotropic effect and results in a decrease in systemic vascular resistance."( Foulds, R; Jaski, BE; Serruys, PW; Wijns, W, 1986)

Actions

ExcerptReference
"Dopexamine evoked an increase in cardiac index preoperatively. "( Ruokonen, ET; Suojaranta-Ylinen, RT; Takala, JA, 2000)
"The dopexamine-induced increase in gastric mucosal oxygenation was mediated by beta2-adrenoceptors, which explains the superior effects of dopexamine to dopamine on mu-Hbo2."( Fournell, A; Loer, SA; Picker, O; Scheeren, TW; Schwarte, LA, 2002)
"Dopexamine-induced increase in heart rate was potentiated by parasympathetic and ganglionic blockade."( Muir, WW, 1992)
"With dopexamine, the increase in renal blood flow (66%) was less than the increase in cardiac index, while renal vascular resistance and systemic vascular resistance declined to almost the same extent."( Henning, H; Sonntag, H; Stephan, H; Yoshimine, K, 1990)
"Dopexamine, because it combines some of the properties of dopamine and salbutamol, may have a role in the management of severe low output cardiac failure."( Bayliss, J; Poole-Wilson, P; Thomas, L, 1987)

Treatment

ExcerptReference
"The dopexamine treated patients had lower myocardial oxygen consumption (9310+/-2243 mmHg O2/sec vs. "( Arlt, A; El Mokhtari, NE; Lins, M; Meissner, A, 2008)
"Dopexamine treatment was associated with impaired organ function and an increased duration of ventilation and ICU stay compared with patients who received dopamine treatment. "( Baur, H; Grotz, MR; Hildebrand, F; Krettek, C; Mahlke, L; Pape, HC; Probst, C; van Griensven, M, 2010)
"The dopexamine treated patients had lower myocardial oxygen consumption (9310 +/- 2243 mmHg O2/sec vs. "( Arlt, A; El Mokhtari, NE; Lins, M; Meissner, A, 2007)
"The dopexamine treated patients had a significantly longer period of low pHi but the pH-gap i.e."( Gårdebäck, M; Ohquist, G; Settergren, G; Tirén, C, 1995)
"Dopexamine treatment was associated with higher lactate levels and increased heart rate (P<0.05) during aortic cross-clamping."( Studer, W; Wu, X, 2000)
"Pretreatment with dopexamine, a dopamine receptor (DA1) and beta 2 adrenoceptor agonist significantly enhanced survival upto 70%."( Jacinto, SM; Jandhyala, BS; Lokhandwala, MF, 1994)
"Rats treated with dopexamine had higher renal Na+ and K+ excretion than dopamine-treated rats."( Eleno, N; Gömez-Garre, DN; López-Farré, A; López-Novoa, JM, 1996)
"Treatment with dopexamine does not improve the pancreatic microcirculation or reduce the extent of acinar cell injury in acute necrotising pancreatitis and is therefore unlikely to be of benefit in patients with pancreatitis."( Alhan, E; Cicek, R; Deger, O; Erçin, C; Küçüktülü, U, 2001)

Drug Classes (1)

ClassDescription
catecholamine4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency16.36840.002541.796015,848.9004AID1347395; AID1347397; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency4.05590.01846.806014.1254AID624172; AID743262
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency31.67680.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency8.61520.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259377
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.73770.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.60070.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.31960.001530.607315,848.9004AID1224848; AID1224849; AID1259401; AID1259403
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.03510.001628.015177.1139AID1224843; AID1224895
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.19650.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.68520.000323.4451159.6830AID743065; AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.77870.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (306)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (16.67)18.7374
1990's155 (50.65)18.2507
2000's77 (25.16)29.6817
2010's16 (5.23)24.3611
2020's7 (2.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials76 (23.97%)5.53%
Reviews29 (9.15%)6.00%
Case Studies3 (0.95%)4.05%
Observational0 (0.00%)0.25%
Other209 (65.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study[NCT01418118]Phase 425 participants (Actual)Interventional2008-10-31Completed
Prospective, Randomized Study on Two Parallel Groups Comparing Dopexamine and Norepinephrine in Combination to Epinephrine Alone on Systemic and Pulmonary Hemodynamics, Gastric Mucosal Perfusion, and Oxidative Stress in Septic Shock[NCT00134212]Phase 220 participants Interventional2002-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
amrinone[no description available]medium50bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
milrinone[no description available]medium40bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
pimobendan[no description available]medium20benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
vesnarinone[no description available]medium10organic molecular entity
dobutamine[no description available]medium630catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
dobutamine[no description available]medium6312catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
prenalterol[no description available]medium10aromatic ether
enoximone[no description available]medium30aromatic ketone
piroximone[no description available]medium30
imazodan[no description available]medium10
ibopamine[no description available]medium40benzoate ester;
phenols
buquineran[no description available]medium10
carbazeran[no description available]medium10
3-amino-6-methyl-5-phenyl-2(1h)-pyridinone[no description available]medium10
xamoterol[no description available]medium10morpholines
4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone[no description available]medium10
pelrinone[no description available]medium10
quazinone[no description available]medium10
lixazinone[no description available]medium10
adenine[no description available]medium106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
quinacrine[no description available]medium10acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
betaine[no description available]medium10amino-acid betaine;
glycine derivative		fundamental metabolite
carnitine[no description available]medium10amino-acid betainehuman metabolite;
mouse metabolite
coumarin[no description available]medium10coumarinsfluorescent dye;
human metabolite;
plant metabolite
bupropion[no description available]medium10aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
guaiacol[no description available]medium10guaiacolsdisinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite
histamine[no description available]medium20aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
acetanilide[no description available]medium10acetamides;
anilide		analgesic
pyridoxine[no description available]medium10hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
enprofylline[no description available]medium10oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
oxyquinoline[no description available]medium10monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
tacrine[no description available]medium10acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
acetaminophen[no description available]medium10acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetarsol[no description available]medium10acetamides;
anilide
ethacridine[no description available]medium10acridines
4-(acetylamino)benzeneacetic acid[no description available]medium10acetamides;
anilide
adiphenine[no description available]medium10diarylmethane
aklomide[no description available]medium10carbonyl compound;
organohalogen compound
albuterol[no description available]medium20phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
altretamine[no description available]medium10triamino-1,3,5-triazine
aminoglutethimide[no description available]medium10dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid[no description available]medium10N-acylglycineDaphnia magna metabolite
amiodarone[no description available]medium101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amlodipine[no description available]medium10dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amodiaquine[no description available]medium10aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
amoxapine[no description available]medium10dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
amprolium[no description available]medium10pyridinium ioncoccidiostat
antazoline[no description available]medium10aromatic amine;
imidazolines;
tertiary amino compound		cholinergic antagonist;
H1-receptor antagonist;
xenobiotic
antipyrine[no description available]medium10pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol[no description available]medium10aporphine alkaloid
arecoline[no description available]medium10enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
astemizole[no description available]medium10benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
azathioprine[no description available]medium10aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
bendroflumethiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benserazide[no description available]medium10carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzocaine[no description available]medium10benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
benzothiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
bepridil[no description available]medium10pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
betaxolol[no description available]medium10propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol[no description available]medium10carbamate ester;
quaternary ammonium ion		muscarinic agonist
bisacodyl[no description available]medium10diarylmethane
bretylium[no description available]medium10quaternary ammonium ionadrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
bromhexine[no description available]medium10organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
seratrodast[no description available]medium10organic molecular entity
bumetanide[no description available]medium10amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
buspirone[no description available]medium10azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan[no description available]medium10methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
butacaine[no description available]medium10benzoate ester
butamben[no description available]medium10amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline		local anaesthetic
caffeine[no description available]medium10purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil[no description available]medium20aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbamylcholine[no description available]medium10
carbamazepine[no description available]medium10dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbinoxamine[no description available]medium10monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carmustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carteolol[no description available]medium10quinolone;
secondary alcohol		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
chloroxylenol[no description available]medium10monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpromazine[no description available]medium10organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide[no description available]medium10monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
cimetidine[no description available]medium10aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
aricine[no description available]medium10cinchona alkaloid
ciprofloxacin[no description available]medium10aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
clomiphene[no description available]medium10tertiary amineestrogen antagonist;
estrogen receptor modulator
clomipramine[no description available]medium10dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clotrimazole[no description available]medium10conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cloxyquin[no description available]medium10organochlorine compound;
quinolines
cromolyn[no description available]medium10chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
cyclandelate[no description available]medium10carboxylic ester;
secondary alcohol		vasodilator agent
cyclobenzaprine[no description available]medium10carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
dapsone[no description available]medium10substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
debrisoquin[no description available]medium10carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
desipramine[no description available]medium30dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
diazoxide[no description available]medium10benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dibenzothiophene[no description available]medium10dibenzothiophenes;
mancude organic heterotricyclic parent		keratolytic drug
dibucaine[no description available]medium10aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
dichlorphenamide[no description available]medium10dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine[no description available]medium10carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
dilacor xr[no description available]medium10acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound
dimethadione[no description available]medium10oxazolidinone
diphenylpyraline[no description available]medium10piperidines;
tertiary amine		cholinergic antagonist;
H1-receptor antagonist
disulfiram[no description available]medium10organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
valproic acid[no description available]medium10branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
donepezil[no description available]medium10aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
doxylamine[no description available]medium10pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
droperidol[no description available]medium10aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
dyclonine[no description available]medium10aromatic ketone;
piperidines		topical anaesthetic
dyphylline[no description available]medium10oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
ebselen[no description available]medium10benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
econazole[no description available]medium10dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
profenamine[no description available]medium10phenothiazines;
tertiary amino compound		adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist
ethosuximide[no description available]medium10dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
etidronate[no description available]medium101,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
felbamate[no description available]medium10carbamate esteranticonvulsant;
neuroprotective agent
fenoldopam[no description available]medium170benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoldopam[no description available]medium172benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
berotek[no description available]medium20resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
berotek[no description available]medium21resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
flecainide[no description available]medium10aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fluphenazine[no description available]medium10N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil[no description available]medium10ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
fluorouracil[no description available]medium10nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
flurbiprofen[no description available]medium10fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flutamide[no description available]medium10(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
furosemide[no description available]medium20chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin[no description available]medium10gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
glafenine[no description available]medium10aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide[no description available]medium10N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glimepiride[no description available]medium10sulfonamide
glyburide[no description available]medium10monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
guaifenesin[no description available]medium10methoxybenzenes
guanethidine[no description available]medium10azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
haloperidol[no description available]medium10aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
hexoprenaline[no description available]medium10
hexamethylene bisacetamide[no description available]medium10acetamides
hycanthone[no description available]medium10thioxanthenesmutagen;
schistosomicide drug
hydralazine[no description available]medium10azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydroflumethiazide[no description available]medium10benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxyzine[no description available]medium10hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ibuprofen[no description available]medium10monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine[no description available]medium10primary amine
indapamide[no description available]medium10indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indomethacin[no description available]medium20aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iodoquinol[no description available]medium10monohydroxyquinoline;
organoiodine compound		antiamoebic agent;
antibacterial agent;
antiprotozoal drug;
antiseptic drug
iproniazid[no description available]medium10carbohydrazide;
pyridines
isoetharine[no description available]medium10catecholamine
isoniazid[no description available]medium10carbohydrazideantitubercular agent;
drug allergen
isoproterenol[no description available]medium110catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine[no description available]medium20alkylbenzene
ketoconazole[no description available]medium10dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketotifen[no description available]medium10cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
labetalol[no description available]medium10benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
leflunomide[no description available]medium10(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole[no description available]medium10nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
losartan[no description available]medium10biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
ly 171883[no description available]medium10acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
meclofenamic acid[no description available]medium10aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
memantine[no description available]medium10adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
mephenesin[no description available]medium10aromatic ether;
glycerol ether
mephenytoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
benzoic acid [2-methyl-2-(propylamino)propyl] ester[no description available]medium10benzoate ester
mesalamine[no description available]medium10amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
metaproterenol[no description available]medium10aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
metformin[no description available]medium10guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methapyrilene[no description available]medium10ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methocarbamol[no description available]medium10aromatic ether;
carbamate ester;
secondary alcohol
metyrapone[no description available]medium10aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mianserin[no description available]medium10dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole[no description available]medium10dichlorobenzene;
ether;
imidazoles
minoxidil[no description available]medium10dialkylarylamine;
tertiary amino compound
mitotane[no description available]medium10diarylmethane
acecainide[no description available]medium10acetamides;
benzamides		anti-arrhythmia drug
nadolol[no description available]medium10tetralins
nafronyl[no description available]medium10naphthalenes
naftopidil[no description available]medium10piperazines
naphazoline[no description available]medium10naphthalenes
nefazodone[no description available]medium10aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
neostigmine[no description available]medium10quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine[no description available]medium10cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nicardipine[no description available]medium10benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine[no description available]medium30C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nilvadipine[no description available]medium10dihydropyridine;
isopropyl ester;
methyl ester;
nitrile
nitromide[no description available]medium10
nomifensine[no description available]medium10isoquinolinesdopamine uptake inhibitor
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one[no description available]medium10isoquinolines
nylidrin[no description available]medium10alkylbenzene
ofloxacin[no description available]medium103-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
orphenadrine[no description available]medium10ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxethazaine[no description available]medium10amino acid amide
oxibendazole[no description available]medium10benzimidazoles;
carbamate ester
oxprenolol[no description available]medium10aromatic ether
benoxinate[no description available]medium10amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound		drug allergen;
local anaesthetic;
topical anaesthetic
papaverine[no description available]medium10benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pargyline[no description available]medium10aromatic amine
pentamidine[no description available]medium10aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
perhexiline[no description available]medium10piperidinescardiovascular drug
perphenazine[no description available]medium10N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacemide[no description available]medium10acetamides
1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate[no description available]medium10pyrroloindole
pinacidil[no description available]medium10pyridines
pioglitazone[no description available]medium10aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piracetam[no description available]medium10organonitrogen compound;
organooxygen compound
pirenzepine[no description available]medium10pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
piretanide[no description available]medium10aromatic ether
practolol[no description available]medium10acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
duodote[no description available]medium10pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
praziquantel[no description available]medium10isoquinolines
prazosin[no description available]medium20aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine[no description available]medium10aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
proadifen[no description available]medium10diarylmethane
probenecid[no description available]medium10benzoic acids;
sulfonamide		uricosuric drug
probucol[no description available]medium10dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procaine[no description available]medium10benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
prochlorperazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
propafenone[no description available]medium10aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propranolol[no description available]medium60naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
protriptyline[no description available]medium10carbotricyclic compoundantidepressant
pyrilamine[no description available]medium10aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
pyrimethamine[no description available]medium10aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
riluzole[no description available]medium10benzothiazoles
risperidone[no description available]medium101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rofecoxib[no description available]medium10butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
roxarsone[no description available]medium102-nitrophenols;
organoarsonic acid		agrochemical;
animal growth promotant;
antibacterial drug;
coccidiostat
salicylamide[no description available]medium10phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
salicylsalicylic acid[no description available]medium10benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
sulfadiazine[no description available]medium10pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
spiperone[no description available]medium10aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
imatinib[no description available]medium10aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
succinylsulfathiazole[no description available]medium101,3-thiazoles
sulfacetamide[no description available]medium10N-sulfonylcarboxamide;
substituted aniline		antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine[no description available]medium10aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfamethazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole[no description available]medium10sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole[no description available]medium10isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfisoxazole[no description available]medium10isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulpiride[no description available]medium10benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
telenzepine[no description available]medium10benzodiazepine
terfenadine[no description available]medium10diarylmethane
tetracaine[no description available]medium10benzoate ester;
tertiary amino compound		local anaesthetic
tetrahydroxy-1,4-quinone[no description available]medium10hydroxybenzoquinonekeratolytic drug
thalidomide[no description available]medium10phthalimides;
piperidones
thiabendazole[no description available]medium101,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
2-thiosalicylic acid[no description available]medium10sulfanylbenzoic acidantipyretic;
non-narcotic analgesic
thioridazine[no description available]medium10phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
thiotepa[no description available]medium10aziridines
ticlopidine[no description available]medium10monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tolazamide[no description available]medium10N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolazoline[no description available]medium10imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
tolbutamide[no description available]medium10N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolnaftate[no description available]medium10monothiocarbamic esterantifungal drug
trapidil[no description available]medium10triazolopyrimidines
trifluoperazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trifluperidol[no description available]medium10aromatic ketone
triflupromazine[no description available]medium10organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trimebutine[no description available]medium10trihydroxybenzoic acid
trimeprazine[no description available]medium10phenothiazines
trimethoprim[no description available]medium10aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trioxsalen[no description available]medium10psoralensdermatologic drug;
photosensitizing agent
troglitazone[no description available]medium10chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
tropicamide[no description available]medium10acetamides
tulobuterol[no description available]medium10organochlorine compound
urapidil[no description available]medium10piperazines
urethane[no description available]medium10carbamate esterfungal metabolite;
mutagen
venlafaxine[no description available]medium10cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
xylazine[no description available]medium101,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
xylometazoline[no description available]medium10alkylbenzene
prednisolone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
estriol[no description available]medium1016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
reserpine[no description available]medium10alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
phentolamine[no description available]medium10imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
piperonyl butoxide[no description available]medium10benzodioxolespesticide synergist
estrone[no description available]medium1017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
penicillin g[no description available]medium10penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
metaraminol[no description available]medium10phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
chloramphenicol[no description available]medium10C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
ethinyl estradiol[no description available]medium1017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
apomorphine[no description available]medium10aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
ethopabate[no description available]medium10amidobenzoic acid
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acepromazine[no description available]medium20aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound		phenothiazine antipsychotic drug
methoxamine[no description available]medium20amphetaminesalpha-adrenergic agonist;
antihypotensive agent
cloxacillin[no description available]medium10penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
zoxazolamine[no description available]medium10benzoxazole
berlition[no description available]medium10dithiolanes;
heterocyclic fatty acid;
lipoic acid;
thia fatty acid		cofactor;
nutraceutical;
prosthetic group
desoxycorticosterone[no description available]medium1020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
colchicine[no description available]medium10alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
norethindrone[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
trifluridine[no description available]medium10nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
mepenzolate bromide[no description available]medium10diarylmethane
pantothenic acid[no description available]medium10pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
sulfachlorpyridazine[no description available]medium10organochlorine compound;
pyridazines;
sulfonamide		antibacterial drug;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
methylprednisolone[no description available]medium106-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
phensuximide[no description available]medium10pyrrolidines
dimethisoquin[no description available]medium10isoquinolines
synephrine[no description available]medium10ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
pyridostigmine bromide[no description available]medium10pyridinium salt
benzonatate[no description available]medium10benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
phenformin[no description available]medium10biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
cinchophen[no description available]medium10quinolines
chloroprocaine[no description available]medium10benzoate ester;
monochlorobenzenes		central nervous system depressant;
local anaesthetic;
peripheral nervous system drug
yohimbine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
ditiocarb[no description available]medium10dithiocarbamic acidschelator;
copper chelator
propantheline bromide[no description available]medium10xanthenes
fluorometholone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
dihydralazine[no description available]medium10phthalazines
dimenhydrinate[no description available]medium10diarylmethane
4-(benzoylamino)-2-hydroxybenzoic acid[no description available]medium10benzamides
megestrol acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
trimetozine[no description available]medium10morpholines
docosanol[no description available]medium10docosanol;
long-chain primary fatty alcohol		antiviral drug;
plant metabolite
tetramethylpyrazine[no description available]medium10alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
flurandrenolone[no description available]medium1021-hydroxy steroid
amiloride[no description available]medium10aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
pimozide[no description available]medium10benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
flumethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
sulfadoxine[no description available]medium10pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
dicloxacillin[no description available]medium10dichlorobenzene;
penicillin		antibacterial drug
tranylcypromine[no description available]medium102-phenylcyclopropan-1-amine
beclomethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
floxacillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
(1S,2R)-tranylcypromine[no description available]medium102-phenylcyclopropan-1-amine
parbendazole[no description available]medium10benzimidazoles;
carbamate ester
levamisole[no description available]medium106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
danazol[no description available]medium1017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
metergoline[no description available]medium10carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
fenclozic acid[no description available]medium10
capobenic acid[no description available]medium10benzamides
diftalone[no description available]medium10
carbimazole[no description available]medium101,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
ursodeoxycholic acid[no description available]medium10bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
rose bengal b disodium salt[no description available]medium10
amoxicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
indoramin[no description available]medium10tryptamines
carbidopa[no description available]medium10catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
methyldopa[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
bezafibrate[no description available]medium10aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
benoxaprofen[no description available]medium101,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
torsemide[no description available]medium10aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
piperacillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
indalpine[no description available]medium10indoles
lidamidine[no description available]medium10ureas
talniflumate[no description available]medium10benzofurans
nedocromil[no description available]medium10dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
dazoxiben[no description available]medium10
tolrestat[no description available]medium10naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
simvastatin[no description available]medium10delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
remoxipride[no description available]medium10dimethoxybenzene
quinapril[no description available]medium10dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
alpidem[no description available]medium10imidazoles
lonapalene[no description available]medium10naphthalenes;
organochlorine compound
ipsapirone[no description available]medium10N-arylpiperazine
sematilide[no description available]medium10
zileuton[no description available]medium101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
remacemide[no description available]medium10stilbenoid
valsartan[no description available]medium10biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
paroxetine hydrochloride[no description available]medium10hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
verapamil hydrochloride[no description available]medium10
fenclofenac[no description available]medium10aromatic ether
proxicromil[no description available]medium10
torbafylline[no description available]medium10
sertraline[no description available]medium10dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
enrofloxacin[no description available]medium10cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
uk 68798[no description available]medium10aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
mepindolol[no description available]medium10indoles
fpl 52791[no description available]medium10
epanolol[no description available]medium10acetamides
methotrimeprazine[no description available]medium10phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
rosiglitazone[no description available]medium10aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
nicotine[no description available]medium103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
levcromakalim[no description available]medium101-benzopyran
hexylcaine hydrochloride[no description available]medium10
imipenem, anhydrous[no description available]medium10beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sr141716[no description available]medium10amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous[no description available]medium10primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
fpl 55712[no description available]medium10aromatic ketone
sivelestat[no description available]medium10N-acylglycine;
pivalate ester
fpl-52694[no description available]medium10
ramatroban[no description available]medium10organic molecular entity
methotrexate[no description available]medium10dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
xaliproden[no description available]medium10(trifluoromethyl)benzenes;
naphthalenes;
tertiary amino compound;
tetrahydropyridine		serotonergic agonist
n-isobutyrylcysteine[no description available]medium10
dexpanthenol[no description available]medium10amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
quilostigmine[no description available]medium10pyrroloindole
imiloxan[no description available]medium10benzodioxine
aspartame[no description available]medium10carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
tempol[no description available]medium10aminoxyls;
hydroxypiperidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger
levofloxacin[no description available]medium109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
vatalanib[no description available]medium10monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
moxifloxacin[no description available]medium10aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
clevidipine[no description available]medium10dihydropyridine
hyoscyamine[no description available]medium10tropane alkaloid
naproxen[no description available]medium10methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
lactitol[no description available]medium10glycosyl alditolcathartic;
excipient;
laxative
fpl 52757[no description available]medium10
paromomycin[no description available]medium10amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
fpl 59257[no description available]medium10
atropine[no description available]medium20
ropivacaine[no description available]medium20piperidinecarboxamide;
ropivacaine		local anaesthetic
erlotinib[no description available]medium10aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
zeneca zd 6169[no description available]medium10
sibenadet[no description available]medium10
latrepirdine[no description available]medium10methylpyridines;
pyridoindole		geroprotector
ramelteon[no description available]medium10indanes
lapatinib[no description available]medium10furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
cortisone[no description available]medium1011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
phenethicillin[no description available]medium10penicillin allergen;
penicillin
ouabain[no description available]medium1011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
salicin[no description available]medium10aromatic primary alcohol;
aryl beta-D-glucoside;
benzyl alcohols		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
digitoxin[no description available]medium10cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
linezolid[no description available]medium10acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
(S)-bicalutamide[no description available]medium10N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
devazepide[no description available]medium101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
halcinonide[no description available]medium10organic molecular entitySMO receptor agonist
metrizamide[no description available]medium10amino sugar
tretinoin[no description available]medium10retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
melphalan[no description available]medium10L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlorprothixene[no description available]medium10chlorprothixene
etomidate[no description available]medium10ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
methylthiouracil[no description available]medium10pyrimidone
crotamiton[no description available]medium10
flunarizine[no description available]medium10diarylmethane
thiothixene[no description available]medium10N-methylpiperazineanticoronaviral agent
benztropine[no description available]medium10diarylmethane
methimazole[no description available]medium101,3-dihydroimidazole-2-thionesantithyroid drug
sulindac[no description available]medium10monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
capsaicin[no description available]medium10capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
digoxin[no description available]medium10cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
tamoxifen[no description available]medium10stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ethionamide[no description available]medium10pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
scopolamine[no description available]medium103-hydroxy carboxylic acid
ranitidine[no description available]medium10C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
almokalant[no description available]medium10
quinine[no description available]medium10cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
vx-745[no description available]medium10aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
deracoxib[no description available]medium10organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dasatinib[no description available]medium101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
2-aminohippuric acid[no description available]medium10N-acylglycine
rs-130830[no description available]medium10
sitagliptin[no description available]medium10triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
tolcapone[no description available]medium102-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
dinoprostone[no description available]medium20prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
vitamin k semiquinone radical[no description available]medium10
beta carotene[no description available]medium10carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
pheniramine maleate[no description available]medium10organic molecular entity
triprolidine[no description available]medium10N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
homatropine[no description available]medium10tropane alkaloid
cyclosporine[no description available]medium10homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
levetiracetam[no description available]medium10pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
naloxone[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
sirolimus[no description available]medium10antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate[no description available]medium10cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
ar c67085mx[no description available]medium10
desoximetasone[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
sb 223412[no description available]medium10
su 11248[no description available]medium10monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
naltrexone[no description available]medium10cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
cefixime[no description available]medium10cephalosporinantibacterial drug;
drug allergen
zimeldine[no description available]medium10styrenes
enalaprilat anhydrous[no description available]medium20dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
tiotropium[no description available]medium10
guanabenz[no description available]medium10dichlorobenzene
nw 1029[no description available]medium10
ici d1542[no description available]medium10
gavestinel[no description available]medium10
1-methyl-d-lysergic acid butanolamide[no description available]medium10ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
nitrofurantoin[no description available]medium10imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
dantrolene[no description available]medium10
tipredane[no description available]medium103-hydroxy steroidandrogen
bentiromide[no description available]medium10dipeptidediagnostic agent;
indicator;
reagent
gemifloxacin[no description available]medium101,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
utibapril[no description available]medium10
zd 9379[no description available]medium10
ly 450139[no description available]medium10peptide
cangrelor[no description available]medium10adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
sch 527123[no description available]medium10
linaprazan[no description available]medium10
lecozotan[no description available]medium10
ar c155858[no description available]medium10
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one[no description available]medium10methoxybenzenes;
substituted aniline
scopolamine hydrobromide[no description available]medium10
azd 7545[no description available]medium10benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
clavulanate potassium[no description available]medium10potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
cytomel[no description available]medium10organic sodium salt
a 967079[no description available]medium10
pht 427[no description available]medium10
dicumarol[no description available]medium10hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
warfarin[no description available]medium10benzenes;
hydroxycoumarin;
methyl ketone
acyclovir[no description available]medium102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
folic acid[no description available]medium10folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
clozapine[no description available]medium10benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine[no description available]medium10dacarbazine
sildenafil[no description available]medium10piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
olanzapine[no description available]medium10benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
leucovorin[no description available]medium10formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
carbadox[no description available]medium10quinoxaline derivative
fenobam[no description available]medium10ureas
arginine vasopressin[no description available]medium20vasopressincardiovascular drug;
hematologic agent;
mitogen
pituitrin[no description available]medium10
monoethylglycinexylidide[no description available]medium33amino acid amidedrug metabolite
lidocaine[no description available]medium33benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
interleukin-8[no description available]medium11
lactic acid[no description available]medium1372-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
cardiovascular agents[no description available]medium21
calca protein, human[no description available]medium11
ephedrine[no description available]medium10phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
indocyanine green[no description available]medium641,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
iloprost[no description available]medium32carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
malondialdehyde[no description available]medium10dialdehydebiomarker
mannitol[no description available]medium10mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
atrial natriuretic factor[no description available]medium31polypeptide
creatine[no description available]medium11glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
bupivacaine[no description available]medium10aromatic amide;
piperidinecarboxamide;
tertiary amino compound
procaterol[no description available]medium40quinolines
sodium metabisulfite[no description available]medium10inorganic sodium saltfood antioxidant
sulfites[no description available]medium10divalent inorganic anion;
sulfur oxide;
sulfur oxoanion
technetium tc 99m sestamibi[no description available]medium10
ici 118551[no description available]medium70aromatic ether;
indanes;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
bisoprolol[no description available]medium10secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
amitriptyline[no description available]medium10carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
raclopride[no description available]medium10salicylamides
sk&f-38393[no description available]medium40benzazepine;
catechols;
secondary amino compound
allopurinol[no description available]medium20nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
xanthine[no description available]medium30xanthineSaccharomyces cerevisiae metabolite
halothane[no description available]medium41haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
thromboxane a2[no description available]medium10epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid[no description available]medium10
propofol[no description available]medium10phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
aldosterone[no description available]medium1011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
corticosterone[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
cocaine[no description available]medium20benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
felodipine[no description available]medium10dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
nitroglycerin[no description available]medium20nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
impromidine[no description available]medium10
2-naphthol[no description available]medium10naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
ng-nitroarginine methyl ester[no description available]medium10alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
bradykinin[no description available]medium10oligopeptidehuman blood serum metabolite;
vasodilator agent
rhamnose[no description available]medium10L-rhamnose
lactulose[no description available]medium10
phenylephrine[no description available]medium30phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
thromboxane b2[no description available]medium10thromboxanes Bhuman metabolite;
mouse metabolite
acetylcysteine[no description available]medium10acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
pentoxifylline[no description available]medium10oxopurine
alanine[no description available]medium22alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
glutamine[no description available]medium11amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
deoxyepinephrine[no description available]medium30catecholamine
adenosine monophosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
adenosine diphosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
phosphocreatine[no description available]medium10phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
enalapril[no description available]medium10dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
clonidine[no description available]medium10clonidine;
imidazoline
idazoxan[no description available]medium10benzodioxine;
imidazolines		alpha-adrenergic antagonist
mocetinostat[no description available]medium11aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
glutamic acid[no description available]medium11glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
ceruletide[no description available]medium10oligopeptidediagnostic agent;
gastrointestinal drug
dihydrotestosterone[no description available]medium1117beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
atenolol[no description available]medium10ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
flosequinan[no description available]medium10quinolines
sulmazole[no description available]medium10imidazopyridine;
sulfoxide		adenosine A1 receptor antagonist;
cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ketanserin[no description available]medium10aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
zinterol[no description available]medium10
cyclic gmp[no description available]medium113',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
dinoprost[no description available]medium10monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
captopril[no description available]medium10alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cgp 20712a[no description available]medium10
tyramine[no description available]medium20monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
hexamethonium[no description available]medium10quaternary ammonium salt
pentobarbital[no description available]medium10barbituratesGABAA receptor agonist
racepinephrine[no description available]low00catecholamine
norepinephrine, (+,-)-isomer[no description available]low00catecholaminehuman xenobiotic metabolite
normetanephrine[no description available]low00catecholamine
n,n-di-n-propyldopamine[no description available]low00catecholamine
nordefrin[no description available]low00catecholamine
oxidopamine[no description available]low00benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
metanephrine[no description available]low00catecholamine
arbutamine[no description available]low00catecholaminebeta-adrenergic agonist;
cardiotonic drug
dopamine hydrochloride[no description available]low00catecholamine
5-hydroxydopamine[no description available]low00catecholamine
noradrenaline sulfate[no description available]low00catecholamine
corbadrine[no description available]low00catecholaminealpha-adrenergic agonist;
nasal decongestant;
vasoconstrictor agent
coryneine[no description available]low00catecholamine
L-isoprenaline[no description available]low00catecholamine;
phenylethanolamines		beta-adrenergic agonist;
sympathomimetic agent
epinephrine sulfate[no description available]low00catecholamine
6-nitrodopamine[no description available]low00catecholamine
cysteinyldopa[no description available]low00catecholamine;
zwitterion
ConditionIndicatedRelationship StrengthStudiesTrials
Abdominal Aortic Aneurysm0medium43
Acidosis, Respiratory0medium11
Active Hyperemia0medium11
Acute Disease0medium21
Acute Hypercapnic Respiratory Failure0medium31
Acute Hypoxemic Respiratory Failure0medium31
Acute Kidney Failure0low60
Acute Kidney Injury0low60
Acute Kidney Insufficiency0low60
Acute Liver Injury, Drug-Induced0low10
Acute Necrotizing Pancreatitis0low10
Acute Renal Failure0low60
Acute Renal Injury0low60
Acute Renal Insufficiency0low60
Acute-Phase Reaction0medium11
Acute-Phase State0medium11
Anasarca0low10
Anesthesia0medium112
Aneurysm, Abdominal Aortic0medium43
Angina Pectoris0medium11
Angor Pectoris0medium11
Anoxemia0low70
Anoxia0low70
Anuria0low10
Aortic Aneurysm, Abdominal0medium43
Aortic Diseases0medium11
Arrhythmia0medium31
Arrhythmias, Cardiac0medium31
Arrythmia0medium31
Arterial Hyperemia0medium11
Arterial Obstructive Diseases0medium11
Arterial Occlusive Diseases0medium11
Atrioventricular Nodal Re-Entrant Tachycardia0low10
Atrioventricular Reentrant Tachycardia0low10
Autoimmune Disease0low10
Autoimmune Diseases0low10
Bacteremia0low10
Blood Poisoning0medium61
Blood Pressure, High0low30
Blood Pressure, Low0medium21
Bloodstream Infection0medium61
Blunt Injuries0medium11
Brain Edema0low10
Brain Swelling0low10
Bronchial Neoplasms0medium11
Cancer of Head0medium22
Cancer of Head and Neck0medium22
Cancer of Lung0medium11
Cancer of Neck0medium22
Cancer of the Head0medium22
Cancer of the Head and Neck0medium22
Cancer of the Lung0medium11
Cancer of the Neck0medium22
Cardiac Arrhythmia0medium31
Cardiac Arrhythmias0medium31
Cardiac Complex, Premature0medium21
Cardiac Complexes, Premature0medium21
Cardiac Dysrhythmia0medium31
Cardiac Failure0medium377
Cardiac Output, Low0medium164
Cardiomyopathies0medium22
Cardiomyopathies, Primary0medium22
Cardiomyopathies, Secondary0medium22
Cardiomyopathy, Congestive0medium22
Cardiomyopathy, Dilated0medium22
Cardiomyopathy, Dilated, 1a0medium22
Cardiomyopathy, Dilated, Autosomal Recessive0medium22
Cardiomyopathy, Dilated, CMD1A0medium22
Cardiomyopathy, Dilated, LMNA0medium22
Cardiomyopathy, Dilated, With Conduction Defect 10medium22
Cardiomyopathy, Dilated, with Conduction Deffect10medium22
Cardiomyopathy, Familial Idiopathic0medium22
Cardiomyopathy, Idiopathic Dilated0medium22
Cardiovascular Stroke0low20
Carditis0medium11
Cerebral Edema0low10
Cerebral Edema, Cytotoxic0low10
Cerebral Edema, Vasogenic0low10
Chemical and Drug Induced Liver Injury0low10
Chemically-Induced Liver Toxicity0low10
Chronic Disease0medium41
Chronic Illness0medium41
Chronic Kidney Failure0low10
Chronically Ill0medium41
Circulatory Collapse0low10
Circulatory Failure0low10
Colonic Diseases0low10
Complication, Intraoperative0low10
Complication, Peroperative0low10
Complication, Postoperative0medium147
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Congestive Cardiomyopathy0medium22
Congestive Heart Failure0medium377
Coronary Disease0medium72
Coronary Heart Disease0medium72
Critical Illness0medium92
Critically Ill0medium92
Cytotoxic Brain Edema0low10
Cytotoxic Cerebral Edema0low10
Deficiency, Oxygen0low70
Dilated Cardiomyopathy0medium22
Disease Models, Animal0low180
Disease, Pulmonary0low10
Diseases, Pulmonary0low10
Dropsy0low10
Drug Withdrawal Symptoms0medium11
Drug-Induced Acute Liver Injury0low10
Drug-Induced Liver Disease0low10
Drug-Induced Liver Injury0low10
E coli Infections0low20
E. coli Infection0low20
Ectopic Heartbeats0medium21
Edema0low10
Electrolytes0low10
End-Stage Kidney Disease0low10
End-Stage Renal Disease0low10
Endotoxemia0low90
Endotoxin Shock0medium275
Equine Diseases0low10
Escherichia coli Infections0low20
ESRD0low10
Extrasystole0medium21
Extrasystoles0medium21
Fever, Zika0low10
Gait Disorders, Animal0low10
Head and Neck Cancer0medium22
Head and Neck Neoplasm0medium22
Head and Neck Neoplasms0medium22
Head Cancer0medium22
Head Neoplasm0medium22
Head Neoplasms0medium22
Head, Neck Neoplasms0medium22
Heart Attack0low20
Heart Decompensation0medium377
Heart Disease, Ischemic0low20
Heart Failure0medium377
Heart Failure, Congestive0medium377
Heart Failure, Left-Sided0medium377
Heart Failure, Right-Sided0medium377
Heart Valve Diseases0low10
Heart Valvular Disease0low10
Hemorrhagic Necrotic Pancreatitis0low10
Hemorrhagic Shock0low30
Hepatitis, Drug-Induced0low10
Hepatitis, Toxic0low10
Horse Diseases0low10
Hydrops0low10
Hypercapnic Acute Respiratory Failure0medium31
Hypercapnic Respiratory Failure0medium31
Hyperemia0medium11
Hypertension0low30
Hypotension0medium21
Hypotension, Vascular0medium21
Hypovolemia0medium11
Hypovolemic0medium11
Hypovolemic Shock0low10
Hypoxemia0low70
Hypoxemic Acute Respiratory Failure0medium31
Hypoxemic Respiratory Failure0medium31
Hypoxia0low70
Idiopathic Ventricular Tachycardia0low10
Infections, E coli0low20
Infections, Escherichia coli0low20
Infections, Respiratory0low10
Infections, Respiratory Tract0low10
Infections, Upper Respiratory0low10
Infections, Upper Respiratory Tract0low10
Inflammation0medium62
Inflammatory Response Syndrome, Systemic0medium63
Injuries, Blunt0medium11
Injuries, Multiple0medium11
Injuries, Nonpenetrating0medium11
Injuries, Surgical0low10
Injury, Ischemia-Reperfusion0medium62
Injury, Reperfusion0medium62
Innate Inflammatory Response0medium62
Intestinal Obstruction0low10
Intracranial Edema0low10
Intraoperative Complications0low10
Ischemia0medium72
Ischemia-Reperfusion Injury0medium62
Ischemia, Myocardial0low20
Ischemic Heart Disease0low20
Kidney Diseases0medium31
Kidney Failure, Acute0low60
Kidney Failure, Chronic0low10
Kidney Insufficiency, Acute0low60
Lameness, Animal0low10
Left Ventricular Dysfunction0low10
Left-Sided Heart Failure0medium377
Liver Injury, Drug-Induced0low10
Liver Injury, Drug-Induced, Acute0low10
Low Blood Pressure0medium21
Low Cardiac Output0medium164
Low Cardiac Output Syndrome0medium164
Lung Cancer0medium11
Lung Diseases0low10
Lung Neoplasms0medium11
Mitral Incompetence0low10
Mitral Insufficiency0low10
Mitral Regurgitation0low10
Mitral Valve Incompetence0low10
Mitral Valve Insufficiency0low10
Mitral Valve Regurgitation0low10
MODS0medium83
Multiple Injuries0medium11
Multiple Organ Dysfunction Syndrome0medium83
Multiple Organ Failure0medium83
Multiple Trauma0medium11
Muscle Contraction0low10
Myocardial Diseases0medium22
Myocardial Diseases, Primary0medium22
Myocardial Diseases, Secondary0medium22
Myocardial Failure0medium377
Myocardial Infarct0low20
Myocardial Infarction0low20
Myocardial Ischemia0low20
Myocardiopathies0medium22
Myocarditis0medium11
Neck Cancer0medium22
Neck Neoplasm0medium22
Neck Neoplasms0medium22
Necrotizing Pancreatitis, Acute0low10
Neoplasms, Bronchial0medium11
Neoplasms, Head0medium22
Neoplasms, Head and Neck0medium22
Neoplasms, Lung0medium11
Neoplasms, Neck0medium22
Neoplasms, Pulmonary0medium11
Neoplasms, Upper Aerodigestive Tract0medium22
Nonpenetrating Injuries0medium11
Nonsustained Ventricular Tachycardia0low10
Oliguria0medium31
Organ Dysfunction Syndrome, Multiple0medium83
Organ Failure, Multiple0medium83
Oxygen Deficiency0low70
Palsy0low10
Pancreatic Necrosis0low10
Pancreatitis Necrotising0low10
Pancreatitis Necrotizing0low10
Pancreatitis, Acute Necrotizing0low10
Paralysis0low10
Paroxysmal Supraventricular Tachycardia0low10
Passive Hyperemia0medium11
Peritonitis0low40
Peroperative Complications0low10
Plegia0low10
Poisoning, Blood0medium61
Polytrauma0medium11
Postoperative Complications0medium147
Premature Beats0medium21
Premature Cardiac Complex0medium21
Premature Cardiac Complexes0medium21
Primary Myocardial Diseases0medium22
Primary Peritonitis0low40
Pulmonary Cancer0medium11
Pulmonary Disease0low10
Pulmonary Diseases0low10
Pulmonary Neoplasms0medium11
Pyaemia0medium61
Pyemia0medium61
Pyohemia0medium61
Reaction, Acute-Phase0medium11
Reactive Hyperemia0medium11
Renal Disease, End-Stage0low10
Renal Failure, Acute0low60
Renal Failure, Chronic0low10
Renal Failure, End-Stage0low10
Renal Insufficiency, Acute0low60
Reperfusion Damage0medium62
Reperfusion Injury0medium62
Respiratory Acidosis0medium11
Respiratory Depression0medium31
Respiratory Failure0medium31
Respiratory Infections0low10
Respiratory Insufficiency0medium31
Respiratory Tract Infections0low10
Response, Acute-Phase0medium11
Right-Sided Heart Failure0medium377
Secondary Myocardial Diseases0medium22
Secondary Peritonitis0low40
Sensitivity and Specificity0medium31
Sepsis0medium61
Sepsis Syndrome0medium63
Septic Shock0medium275
Septicemia0medium61
Severe Sepsis0medium61
Shock0low10
Shock, Cardiogenic0low30
Shock, Endotoxic0medium275
Shock, Hemorrhagic0low30
Shock, Toxic0medium275
Stenocardia0medium11
Substance Withdrawal Syndrome0medium11
Surgical Injuries0low10
Symptom Cluster0low10
Syndrome0low10
Systemic Inflammatory Response Syndrome0medium63
Tachyarrhythmia0medium21
Tachycardia0medium21
Tachycardia, Ventricular0low10
Todd Paralysis0low10
Todd's Paralysis0low10
Toxic Hepatitis0low10
Toxic Shock0medium275
Toxic Shock Syndrome0medium275
Trauma, Multiple0medium11
UADT Neoplasm0medium22
UADT Neoplasms0medium22
Upper Aerodigestive Tract Neoplasm0medium22
Upper Aerodigestive Tract Neoplasms0medium22
Upper Respiratory Infections0low10
Upper Respiratory Tract Infection0low10
Upper Respiratory Tract Infections0low10
Valvular Heart Diseases0low10
Vascular Hypotension0medium21
Vasogenic Brain Edema0low10
Vasogenic Cerebral Edema0low10
Venous Congestion0medium11
Venous Engorgement0medium11
Ventilatory Depression0medium31
Ventricular Dysfunction, Left0low10
Ventricular Tachyarrhythmias0low10
Ventricular Tachycardia0low10
Withdrawal Symptoms0medium11
Wounds, Multiple0medium11
Wounds, Nonpenetrating0medium11
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (2)

ArticleYear
The effects of dopexamine in bupivacaine and ropivacaine induced cardiotoxicity in isolated rat heart.
Saudi medical journal, Volume: 27, Issue: 8		2006
Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study.
Journal of the American College of Cardiology, Volume: 18, Issue: 2		1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (2)

ArticleYear
Low potential of dobutamine and dopexamine to block intestinal peristalsis as compared with other catecholamines.
Critical care medicine, Volume: 28, Issue: 8		2000
Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs.
Journal of autonomic pharmacology, Volume: 16, Issue: 5		1996
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (5)

ArticleYear
Effect of adding dopexamine to intraoperative volume expansion in patients undergoing major elective abdominal surgery.
British journal of anaesthesia, Volume: 91, Issue: 5		2003
Effects of dopexamine and volume loading on hemodynamics and oxygenation parameters in patients undergoing pulmonary resection.
Acta anaesthesiologica Scandinavica, Volume: 44, Issue: 7		2000
[The effects of dopexamine. Transpulmonary shunt volume in thoracic surgical procedures with one-lung respiration].
Der Anaesthesist, Volume: 46, Issue: 9		1997
Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting.
Anesthesia and analgesia, Volume: 84, Issue: 5		1997
Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis.
Critical care medicine, Volume: 23, Issue: 12		1995
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (3)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Dopamine, dobutamine, and dopexamine. A comparison of renal effects in unanesthetized human volunteers.
Anesthesiology, Volume: 79, Issue: 4		1993
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (26)

ArticleYear
Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients.
Intensive care medicine, Volume: 30, Issue: 6		2004
[The effect of dopexamine and iloprost on plasma disappearance rate of indocyanine green in patients in septic shock].
Der Anaesthesist, Volume: 52, Issue: 11		2003
Dopexamine but not dopamine increases gastric mucosal oxygenation during mechanical ventilation in dogs.
Critical care medicine, Volume: 30, Issue: 4		2002
Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.
Critical care medicine, Volume: 29, Issue: 2		2001
Catecholamines and splanchnic perfusion.
Schweizerische medizinische Wochenschrift, Dec-16, Volume: 130, Issue: 50		2000
Haemodynamic management of a patient with septic shock.
European journal of anaesthesiology, Volume: 17, Issue: 1		2000
Dopexamine increases splanchnic blood flow but decreases gastric mucosal pH in severe septic patients treated with dobutamine.
Critical care medicine, Volume: 27, Issue: 10		1999
Effects of dopamine, dobutamine, dopexamine, phenylephrine, and saline solution on intramuscular blood flow and other cardiopulmonary variables in halothane-anesthetized ponies.
American journal of veterinary research, Volume: 59, Issue: 11		1998
Effects of vasoactive drugs on gastric intramucosal pH.
Critical care medicine, Volume: 26, Issue: 10		1998
Hemodynamic support and the role of dopamine.
Kidney international. Supplement, Volume: 66		1998
Temporal effects of an infusion of dopexamine hydrochloride in horses anesthetized with halothane.
American journal of veterinary research, Volume: 58, Issue: 5		1997
Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs.
Journal of autonomic pharmacology, Volume: 16, Issue: 5		1996
Effects of dopexamine on hemodynamics and oxygen consumption after beta blockade in lambs.
Critical care medicine, Volume: 21, Issue: 5		1993
Comparison of effects of dopamine hydrochloride and dopexamine hydrochloride on abdominal and femoral hemodynamics in anesthetized dogs.
Circulatory shock, Volume: 40, Issue: 3		1993
Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting.
Chest, Volume: 106, Issue: 3		1994
Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.
British journal of pharmacology, Volume: 111, Issue: 1		1994
Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.
British journal of pharmacology, Volume: 115, Issue: 2		1995
Atypical antagonism of D1-receptor-mediated vasodilator response in the perfused kidney by SCH23390.
Pharmacological research, Volume: 31, Issue: 5		1995
Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours' duration for severe congestive heart failure.
The American journal of cardiology, Aug-11, Volume: 62, Issue: 5		1988
Cardiovascular pharmacology of dopexamine in low output congestive heart failure.
The American journal of cardiology, Jul-01, Volume: 62, Issue: 1		1988
Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure.
European heart journal, Volume: 7, Issue: 8		1986
Hemodynamic effects of dopexamine in patients following coronary artery bypass surgery.
Journal of cardiothoracic anesthesia, Volume: 3, Issue: 4		1989
Hemodynamic comparison of dopexamine hydrochloride and dopamine in ischemic left ventricular dysfunction.
The American journal of cardiology, Aug-11, Volume: 62, Issue: 5		1988
[Acute reduction of increased atrial natriuretic peptide level and cyclic guanosine monophosphate in patients with chronic heart failure caused by beta-adrenergic stimulation with dopexamine hydrochloride. Correlation with hemodynamic parameters].
Zeitschrift fur Kardiologie, Volume: 79, Issue: 6		1990
Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
Drugs, Volume: 39, Issue: 2		1990
Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects on hemodynamics and urine output.
The American journal of cardiology, Mar-15, Volume: 65, Issue: 11		1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]